ATRA News and Press, Atara Biotherapeutics Inc. From 11/12/25

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million m...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) PR Newswire Tabelecleucel BLA currently under ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of...

2025-08-11 16:40:41 ET More on Atara Biotherapeutics Atara gets FDA priority review for Tabeelecleucel application Atara gains after insider purchase Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeuti...

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred substantially all operational activities and associated costs related to tab-cel to Pierre Fabre Laboratories Atara has resumed its evaluation of strategic options A...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Atara Biotherapeutics Inc. (ATRA) is expected to report for Q2 2025

2025-07-24 12:31:13 ET Atara Biotherapeutics (NASDAQ: ATRA) has reached a pivotal milestone in its mission to transform treatment options for patients with life-threatening diseases. The U.S. Food and Drug Administration (FDA) has accepted Ataras Biologics License Application (BLA) for ...

2025-07-24 10:49:03 ET More on Atara Biotherapeutics Atara gains after insider purchase Atara Biotherapeutics prices $16M public offering Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics F...